Source: Annual Congress 2003 - Cystic fibrosis bronchiectasis, respiratory viral infections and infection in asthma
Disease area: Airway diseases, Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
A. Kessaris, M. Souli, I. Inglezos, K. Kanellakopoulou, F. Apostolopoulou, E. Giamarellou (Athens, Greece). Efficacy of low-dose, long-term clarithromycin administration in improving the clinical course in cystic fibrosis patients with chronic P. aeruginosa airway colonization. Eur Respir J 2003; 22: Suppl. 45, 3211

Member's Comments

No comment yet.

Related content which might interest you: The efficacy of early eradication therapy in prevention of chronic pseudomonas aeruginosa infection in cystic fibrosis Source: Eur Respir J 2006; 28: Suppl. 50, 486s Year: 2006 Effect of long term treatment with azithromycin on clinical status and lung function parameters in cystic fibrosis patients colonised by pseudomonas aeruginosa Source: Annual Congress 2009 - Cystic fibrosis: advances in clinical research Year: 2009 Interim data from a long-term safety, tolerability, and efficacy study of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonas aeruginosa infection Source: International Congress 2014 – Cystic fibrosis: assessment and treatment Year: 2014 A randomised comparison of two tobramycin formulations in cystic fibrosis (CF) patients with chronic pseudomonas aeruginosa (PA) infection for pharmacokinetic and therapeutic equivalence Source: Annual Congress 2013 –Cystic fibrosis: basic and applied science Year: 2013 The clinical impact of nebulised antibiotics in adults with bronchiectasis and chronic pseudomonas aeruginosa Source: Virtual Congress 2020 – Non-tuberculous mycobacterial infections and bronchiectasis Year: 2020 Long-term efficacy and safety of tobramycin 300mg/4mL nebuliser solution in patients with cystic fibrosis and chronic Pseudomonas aeruginosa infection Source: Annual Congress 2012 - Cystic fibrosis (adults and children): new aspects of risk factors, treatments and diagnosis Year: 2012 Effects of long-term azithromycin treatment in patients with non-cystic fibrosis stable bronchiectasis Source: Annual Congress 2007 - Infectious lung and pleural diseases Year: 2007 Daily versus weekly azithromycin in cystic fibrosis patients Source: Eur Respir J 2007; 30: 487-495 Year: 2007 Pseudomonas aeruginosa in patients with cystic fibrosis - a comparison of early eradication and conventional therapy Source: Eur Respir J 2004; 24: Suppl. 48, 385s Year: 2004 Long-term evaluation of the response to aggressive treatment at the first colonization of P.aeruginosa in cystic fibrosis (CF) Source: Eur Respir J 2001; 18: Suppl. 33, 126s Year: 2001 Long-term administration of aerosolised tobramycin in patients with cystic fibrosis Source: Eur Respir J 2005; 26: Suppl. 49, 619s Year: 2005 The role of inhaled antibiotics in bronchial infection Source: Eur Respir Monogr 2013; 60: 120-126 Year: 2013 Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study Source: Eur Respir J 2013; 41: 1107-1115 Year: 2013 Efficacy of moxifloxacin in the treatment of bronchial colonisation in COPD Source: Eur Respir J 2009; 34: 1066-1071 Year: 2009 Azithromycin in chronic respiratory infections with pseudomonas aeruginosa in patients without cystic fibrosis Source: Annual Congress 2008 - Mechanisms of respiratory infections: interaction between the pathogen and the host Year: 2008 Highly concentrated aerosolized tobramycin in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection Source: Eur Respir J 2005; 26: Suppl. 49, 620s Year: 2005 Effect of azithromycin treatment on inflammation in COPD patients Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies Year: 2019 Doxycycline improves clinical outcomes during cystic fibrosis exacerbations Source: Eur Respir J , 49 (4)  1601102; DOI: 10.1183/13993003.01102-2016 Year: 2017 Efficacy of ciprofloxacin against resistant mucoid or non-mucoid P. aeruginosa isolated from non-cystic fibrosis bronchiectasis (NCFB) patients considering lung pharmacokinetics after ciprofloxacin DPI treatment Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options Year: 2014 The impact of long-term azithromycin on antibiotic resistance in HIV-associated chronic lung disease Source: ERJ Open Res, 8 (1) 00491-2021; 10.1183/23120541.00491-2021 Year: 2022